CBS - The 17th Left Main & Coronary Bifurcation Summit, CBS2025

科学研究

Microthrombi As A Major Cause of Cardiac Injury in COVID-19: A Pathologic Study Older Adults in the Cardiac Intensive Care Unit: Factoring Geriatric Syndromes in the Management, Prognosis, and Process of Care: A Scientific Statement From the American Heart Association Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial Complete Revascularization Versus Culprit Lesion Only in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease: A DANAMI-3-PRIMULTI Cardiac Magnetic Resonance Substudy 中国肺高血压诊断和治疗指南2018 A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: A Report by the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society

Sort by hits |<<... 63 64 65 66 67 68 69 ...>>|

Original ResearchVolume 75, Issue 7, February 2020

JOURNAL：J Am Coll Cardiol. Article Link

Long-Term Exposure to Fine Particulate Matter and Cardiovascular Disease in China

FC Liang, FC Liu, DF Gu et al. Keywords: cardiovascular diseases; cohort study; incidence and mortality; long-term exposure; satellite-based PM2.5 estimation

ABSTRACT

BACKGROUND - Evidence of the effects of long-term fine particulate matter (PM_2.5) exposure on cardiovascular diseases (CVDs) is rare for populations exposed to high levels of PM_2.5 in China and in other countries with similarly high levels.

OBJECTIVES - The aim of this study was to assess the CVD risks associated with long-term exposure to PM_2.5 in China.

METHODS - A nationwide cohort study, China-PAR (Prediction for Atherosclerotic Cardiovascular Disease Risk in China), was used, with 116,972 adults without CVD in 2000 being included. Participants were followed until 2015. Satellite-based PM_2.5 concentrations at 1-km spatial resolution during the study period were used for exposure assessment. A Cox proportional hazards model with time-varying exposures was used to estimate the CVD risks associated with PM_2.5 exposure, adjusting for individual risk factors.

RESULTS - Annual mean concentrations of PM_2.5 at the China-PAR sites ranged from 25.5 to 114.0 μg/m³. For each 10 μg/m³ increase in PM_2.5 exposures, the multivariate-adjusted hazard ratio was 1.251 (95% confidence interval: 1.220 to 1.283) for CVD incidence and 1.164 (95% confidence interval: 1.117 to 1.213) for CVD mortality. The slopes of concentration-response functions of PM_2.5 exposure and CVD risks were steeper at high PM_2.5 levels. In addition, older residents, rural residents, and never smokers were more prone to adverse effects of PM_2.5 exposure.

CONCLUSIONS - This study provides evidence that elevated long-term PM_2.5 exposures lead to increased CVD risk in China. The effects are more pronounced at higher PM_2.5 levels. These findings expand the current knowledge on adverse health effects of severe air pollution and highlight the potential cardiovascular benefits of air quality improvement in China and other low- and middle-income countries.

Abstract

Recommended Article

Long-Term Exposure to Fine Particulate Matter and Cardiovascular Disease in China

ABSTRACT